ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO924

ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Pongpirul, Krit, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand
  • Prasithsirikul, Wisit, Bamrasnaradura Infectious Disease Institute, Nonthaburi, Nonthaburi, Thailand
  • Nopsopon, Tanawin, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand
  • Phutrakool, Phanupong, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand
  • Kantagowit, Piyawat, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand
  • Jongkaewwattana, Anan, National Center of Genetic Engineering and Biotechnology, Pathum Thani, Thailand

This study aimed to evaluate the immunogenicity of two doses of ChAdOx1 nCoV-19 and the immune response post-COVID-19 infection in ESRD with HD patients.


The blood samples were obtained at baseline, 1-month, and 3-month follow-up after each shot or recovery. All participants were measured for anti-spike IgG by the ELISA method using Euroimmun.


This study found a significant increase in anti-spike IgG after 1 month of two-shot ChAdOx1 nCoV-19 vaccination, followed by a significant decrease after 3 months. On the other hand, the anti-spike IgG was maintained in the post-recovery group. There was no significant difference in the change of anti-spike IgG between one-shot ChAdOx1 nCoV-19 vaccinated and post-recovery groups for both 1-month and 3-month follow-ups. The seroconversion rate for the vaccinated group was 60.32% at one-month after one-shot vaccination and slightly dropped to 58.73% at 3-month follow-up, then was 92.06% at one-month after two-shot vaccination and reduced to 82.26% at 3-month follow-up. For the recovered group, the seroconversion rate was 95.65% at one-month post-recovery and 92.50% at 3-month follow-up.


This study established the immunogenicity of two-shot ChAdOx1 nCoV-19 in ESRD patients with HD for humoral immunity. After COVID-19 infection, the humoral immune response was strong and could be maintained for at least three months.

Demographic Data of Participants
Age, year (mean ± SD)54.93 ± 15.2857.63 ± 14.8351.22 ± 15.26
Hypertension89 (81.65%)56 (88.89%)33 (71.74%)
Diabetes mellitus49 (44.95%)33 (52.38%)16 (34.78%)
Coronary artery disease4 (3.67%)3 (4.76%)1 (2.17%)

Data were presented as counts and percentages if not otherwise specified. SD: standard deviation.

Changes in anti-spike IgG in HD patients who received a single dose of ChAdOx1 and who recovered from COVID-19.


  • Government Support – Non-U.S.